Metabolic syndrome in indigenous communities in Mexico: a descriptive and cross-sectional study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
17 Mar 2020
Historique:
received: 30 04 2019
accepted: 20 02 2020
entrez: 19 3 2020
pubmed: 19 3 2020
medline: 23 7 2020
Statut: epublish

Résumé

An Amerindian genetic background could play an important role in susceptibility to metabolic diseases, which have alarmingly increased in recent decades. Mexico has one of the highest prevalences of metabolic disease worldwide. The purpose of this study was to determine the prevalence of metabolic syndrome and its components in a population with high Amerindian ancestry. We performed a descriptive, quantitative, and analytical cross-sectional study of 2596 adult indigenous volunteers from 60 different ethnic groups. Metabolic syndrome and its components were evaluated using the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement criteria. The overall prevalence of metabolic syndrome in the indigenous Mexican population was 50.3%. Although females had a higher prevalence than males (55.6% vs. 38.2%), the males presented with combinations of metabolic syndrome components that confer a higher risk of cardiovascular disease. The most frequent metabolic syndrome component in both genders was low HDL-cholesterol levels (75.8%). Central obesity was the second most frequent component in females (61%), though it had a low prevalence in males (16.5%). The overall prevalence of elevated blood pressure was 42.7% and was higher in males than females (48.8 vs. 40%). We found no gender differences in the overall prevalence of elevated triglycerides (56.7%) or fasting glucose (27.9%). We documented that individuals with Amerindian ancestry have a high prevalence of metabolic syndrome. Health policies are needed to control the development of metabolic disorders in a population with high genetic risk.

Sections du résumé

BACKGROUND BACKGROUND
An Amerindian genetic background could play an important role in susceptibility to metabolic diseases, which have alarmingly increased in recent decades. Mexico has one of the highest prevalences of metabolic disease worldwide. The purpose of this study was to determine the prevalence of metabolic syndrome and its components in a population with high Amerindian ancestry.
METHODS METHODS
We performed a descriptive, quantitative, and analytical cross-sectional study of 2596 adult indigenous volunteers from 60 different ethnic groups. Metabolic syndrome and its components were evaluated using the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement criteria.
RESULTS RESULTS
The overall prevalence of metabolic syndrome in the indigenous Mexican population was 50.3%. Although females had a higher prevalence than males (55.6% vs. 38.2%), the males presented with combinations of metabolic syndrome components that confer a higher risk of cardiovascular disease. The most frequent metabolic syndrome component in both genders was low HDL-cholesterol levels (75.8%). Central obesity was the second most frequent component in females (61%), though it had a low prevalence in males (16.5%). The overall prevalence of elevated blood pressure was 42.7% and was higher in males than females (48.8 vs. 40%). We found no gender differences in the overall prevalence of elevated triglycerides (56.7%) or fasting glucose (27.9%).
CONCLUSIONS CONCLUSIONS
We documented that individuals with Amerindian ancestry have a high prevalence of metabolic syndrome. Health policies are needed to control the development of metabolic disorders in a population with high genetic risk.

Identifiants

pubmed: 32183766
doi: 10.1186/s12889-020-8378-5
pii: 10.1186/s12889-020-8378-5
pmc: PMC7076922
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

339

Références

Expert Rev Endocrinol Metab. 2011 Mar;6(2):279-289
pubmed: 21643518
Diabetes Care. 1994 Sep;17(9):1067-74
pubmed: 7988310
Am J Phys Anthropol. 1986 Oct;71(2):203-7
pubmed: 3099584
Salud Publica Mex. 2010;52 Suppl 1:S11-8
pubmed: 20585723
Intern Med. 2014;53(4):299-305
pubmed: 24531085
Diabetes Care. 2006 Aug;29(8):1866-71
pubmed: 16873794
PLoS One. 2016 Sep 20;11(9):e0163248
pubmed: 27649570
Salud Publica Mex. 2001 Sep-Oct;43(5):459-63
pubmed: 11763694
Nature. 2014 Feb 6;506(7486):97-101
pubmed: 24390345
Hum Mutat. 2009 Jan;30(1):69-78
pubmed: 18683858
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-367
pubmed: 28587579
Sci Rep. 2019 Feb 26;9(1):2748
pubmed: 30808941
Rev Invest Clin. 2011 Mar-Apr;63(2):198-209
pubmed: 21714438
Mol Genet Genomics. 2017 Dec;292(6):1209-1219
pubmed: 28688048
Int J Circumpolar Health. 2007 Sep;66(4):287-307
pubmed: 18018843
Yonsei Med J. 2010 Sep;51(5):676-82
pubmed: 20635441
BMC Genomics. 2016 Jul 21;17:504
pubmed: 27444955
Soc Sci Med. 2011 Dec;73(11):1635-43
pubmed: 22033376
Arch Med Res. 2008 Apr;39(3):352-7
pubmed: 18279710
Rev Invest Clin. 2018;70(5):211-216
pubmed: 30307444
Crit Pathw Cardiol. 2005 Dec;4(4):198-203
pubmed: 18340209
Gac Med Mex. 1997 Nov-Dec;133(6):527-34
pubmed: 9580104
BMC Public Health. 2018 Dec 20;18(1):1397
pubmed: 30572860
Am J Hum Genet. 1962 Dec;14:353-62
pubmed: 13937884
Diabetes Care. 1996 May;19(5):547-8
pubmed: 8732727
Mol Cell Endocrinol. 2015 Feb 15;402:113-9
pubmed: 25578600
Am J Clin Nutr. 2000 Sep;72(3):694-701
pubmed: 10966886
J Ethn Subst Abuse. 2016;15(1):46-72
pubmed: 26114872
Public Health Nutr. 2011 Oct;14(10):1702-13
pubmed: 21486521
Mayo Clin Proc. 2015 Jun;90(6):813-23
pubmed: 26046414
Hum Mol Genet. 2010 Jul 15;19(14):2877-85
pubmed: 20418488
Cardiovasc Diabetol. 2010 Aug 09;9:34
pubmed: 20696055
Diabet Med. 2010 Apr;27(4):412-6
pubmed: 20536512
Nat Commun. 2014 Jun 02;5:3983
pubmed: 24886709
Diabetes Care. 2001 Dec;24(12):2059-64
pubmed: 11723083
Diabetes Care. 2012 Dec;35(12):2591-3
pubmed: 22891255
Metabolism. 2014 Jul;63(7):887-94
pubmed: 24768220

Auteurs

Elvia Cristina Mendoza-Caamal (EC)

Clinical Area, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Francisco Barajas-Olmos (F)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Humberto García-Ortiz (H)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Isabel Cicerón-Arellano (I)

Clinical Area, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Angélica Martínez-Hernández (A)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Emilio J Córdova (EJ)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Marcelino Esparza-Aguilar (M)

Epidemiology Research Department, Instituto Nacional de Pediatría, Insurgentes Sur 3700, Letra C, Colonia Insurgentes Cuicuilco, Delegación Coyoacán, C.P. 04530, Ciudad de México, Mexico.

Cecilia Contreras-Cubas (C)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Federico Centeno-Cruz (F)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Miguel Cid-Soto (M)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Mirna Edith Morales-Marín (ME)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Adriana Reséndiz-Rodríguez (A)

Clinical Area, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Juan Luis Jiménez-Ruiz (JL)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

María Guadalupe Salas-Martínez (MG)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Yolanda Saldaña-Alvarez (Y)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

Elaheh Mirzaeicheshmeh (E)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico.

María Rosalba Rojas-Martínez (MR)

Public Health Research Center, Instituto Nacional de Salud Pública, 7a Cerrada de Fray Pedro de Gante 50, Colonia Sección XVI, Delegación Tlalpan, C.P. 14080, Ciudad de México, Mexico.

Lorena Orozco (L)

Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Genómica, SS, Periférico Sur 4809, Colonia Arenal Tepepan, Delegación Tlalpan, C.P. 14610, Ciudad de México, Mexico. lorozco@inmegen.gob.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH